Real-world data (#RWD) is no longer an afterthought—it’s being integrated earlier in the development lifecycle to:

✅ Map disease progression
✅ Inform trial design

✅ Recruit patients
✅ Benchmark therapies
✅ Identify gaps in access and representation

This shift is particularly impactful in rare and heterogeneous cancers, where traditional trials often struggle with participant diversity and enrollment challenges.

A standout example is the use of circulating tumor DNA (ctDNA) to monitor minimal residual disease (MRD). Sequencing panels applied in real-world settings are now guiding treatment decisions in real time—offering early indicators of therapeutic resistance or efficacy. MRD tracking is emerging as a powerful source of real-world evidence (RWE), helping clinicians personalize care with greater precision.

At Clinakos, we’re advancing this transformation through our innovative Integrated Patient Data™ and Medically Smart AI™, integrating real-world data into our AI-powered platforms to support researchers and clinicians:

• 🔄 Connect fragmented data for a holistic patient view
• 🧠 Generate actionable insights for earlier, smarter interventions
• 🤝 Deliver better, more personalized outcomes in oncology 

As RWE transitions from periphery to the core of oncology research and development, we @Clinakos are ready to accelerate this revolution.

Read the whole article here

👉Reach out to us to learn more at https://lnkd.in/gp3gUmXc

👉Follow us at Clinakos Inc